[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Rohan S, Tu JJ, Kao J, Mukherjee P, Campagne F, Zhou XK, Hyjek E, Alonso MA, Chen YT: Gene expression profiling separates chromophobe renal cell carcinoma from oncocytoma and identifies vesicular transport and cell junction proteins as differentially expressed genes. Clin Cancer Res; 2006 Dec 1;12(23):6937-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling separates chromophobe renal cell carcinoma from oncocytoma and identifies vesicular transport and cell junction proteins as differentially expressed genes.
  • PURPOSE: To compare gene expression profiles of chromophobe renal cell carcinoma (RCC) and benign oncocytoma, aiming at identifying differentially expressed genes.
  • Five of these genes, AP1M2, MAL2, PROM2, PRSS8, and FLJ20171, were shown to effectively separate these two tumor groups by quantitative reverse transcription-PCR using fresh tissue samples, with similar trends seen on formalin-fixed tissues.
  • Immunohistochemical analysis revealed selective expression of MAL2 and claudin 8 in distal renal tubules, with MAL2 antibody showing differential expression between chromophobe RCC and oncocytoma.
  • Functional analyses suggest that genes encoding tight junction proteins and vesicular membrane trafficking proteins, normally expressed in distal nephrons, are retained in chromophobe RCC and lost or consistently down-regulated in oncocytoma, indicating that these two tumor types, believed to be both derived from distal tubules, are likely distinctive in their histogenesis.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Carcinoma, Renal Cell / genetics. Gene Expression Profiling. Kidney Neoplasms / genetics. Membrane Proteins / genetics. Thyroid Neoplasms / genetics. Vesicular Transport Proteins / genetics

  • Genetic Alliance. consumer health - Chromophobe Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Oncocytoma renal.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • GeneTex Inc. NCBI Redirect Page | Genetex Inc. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145811.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AP1M2 protein, human; 0 / Adaptor Protein Complex 1; 0 / Adaptor Protein Complex mu Subunits; 0 / FLJ20171 protein, human; 0 / MAL2 protein, human; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / Myelin and Lymphocyte-Associated Proteolipid Proteins; 0 / PROM2 protein, human; 0 / Proteolipids; 0 / RNA, Messenger; 0 / RNA-Binding Proteins; 0 / Vesicular Transport Proteins; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / prostasin
  •  go-up   go-down


2. Kramer CK, Ferreira N, Silveiro SP, Gross JL, Dora JM, Azevedo MJ: Pituitary gland metastasis from renal cell carcinoma presented as a non-functioning macroadenoma. Arq Bras Endocrinol Metabol; 2010;54(5):498-501
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary gland metastasis from renal cell carcinoma presented as a non-functioning macroadenoma.
  • Five years ago, he underwent a right radical nephrectomy for renal cell carcinoma, followed by chemotherapy and radiotherapy for lung and parotid metastases.
  • The patient underwent a transsphenoidal tumor resection that revealed renal cell carcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Pituitary Neoplasms / secondary
  • [MeSH-minor] Adenoma / diagnosis. Aged. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20694412.001).
  • [ISSN] 1677-9487
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


3. Fedirko V, Bostick RM, Flanders WD, Long Q, Shaukat A, Rutherford RE, Daniel CR, Cohen V, Dash C: Effects of vitamin D and calcium supplementation on markers of apoptosis in normal colon mucosa: a randomized, double-blind, placebo-controlled clinical trial. Cancer Prev Res (Phila); 2009 Mar;2(3):213-23
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ninety-two men and women with at least one pathology-confirmed colorectal adenoma were treated with 2.0 g/d calcium or 800 IU/d vitamin D3, alone or in combination, versus placebo over 6 months.
  • After 6 months of treatment, Bax expression along the full lengths of crypts increased 56% (P = 0.02) in the vitamin D group and 33% in both the calcium (P = 0.31) and calcium plus vitamin D (P = 0.36) groups relative to the placebo group.
  • The vitamin D treatment effect was more pronounced in the upper 40%, or differentiation zone, of crypts (80%; P = 0.01).
  • There were no statistically significant treatment effects on Bcl-2 expression.
  • Overall, these preliminary results suggest that calcium and vitamin D, individually or together, may enhance apoptosis in the normal human colorectal epithelium, and the strongest treatment effects may be vitamin D related and in the upper sections of the colorectal crypts.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CHOLECALCIFEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Pharm Des. 2000 May;6(7):717-32 [10828303.001]
  • [Cites] Gut. 2001 Feb;48(2):238-46 [11156647.001]
  • [Cites] Oncol Rep. 2001 Jul-Aug;8(4):893-7 [11410805.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1267-74 [11751444.001]
  • [Cites] Ann N Y Acad Sci. 2001 Dec;952:73-87 [11795445.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 20;94(6):437-46 [11904316.001]
  • [Cites] Food Chem Toxicol. 2002 Jun;40(6):801-8 [11983275.001]
  • [Cites] Cancer Causes Control. 2002 Apr;13(3):213-20 [12020102.001]
  • [Cites] Nutr Cancer. 2001;41(1-2):150-5 [12094618.001]
  • [Cites] J Natl Cancer Inst. 2003 Jun 18;95(12):896-905 [12813173.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):601-14 [12894248.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 3;95(23):1765-71 [14652238.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):546-52 [15066918.001]
  • [Cites] Cell Calcium. 2004 Mar;35(3):291-5 [15200153.001]
  • [Cites] J Natl Cancer Inst. 1984 Jun;72(6):1323-5 [6587152.001]
  • [Cites] Carcinogenesis. 1988 Jan;9(1):187-90 [2826033.001]
  • [Cites] Am J Epidemiol. 1988 Jan;127(1):188-99 [3337073.001]
  • [Cites] Carcinogenesis. 1989 Apr;10(4):647-9 [2702712.001]
  • [Cites] Cancer Res. 1991 Oct 15;51(20):5608-13 [1913678.001]
  • [Cites] Cancer Res. 1992 Apr 1;52(7 Suppl):2067s-2070s [1544142.001]
  • [Cites] J Cell Biol. 1992 Nov;119(3):493-501 [1400587.001]
  • [Cites] J Nutr. 1993 Jan;123(1):144-52 [8421225.001]
  • [Cites] Epidemiol Rev. 1993;15(2):499-545 [8174669.001]
  • [Cites] Calcif Tissue Int. 1995 Jun;56(6):518-20 [7648477.001]
  • [Cites] J Natl Cancer Inst. 1995 Sep 6;87(17):1307-15 [7658483.001]
  • [Cites] Cancer Lett. 1995 Oct 20;97(1):99-106 [7585485.001]
  • [Cites] Clin Chem. 1996 Apr;42(4):586-92 [8605676.001]
  • [Cites] Methods Enzymol. 1997;282:174-86 [9330287.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Nov;6(11):931-42 [9367067.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Mar;7(3):221-5 [9521437.001]
  • [Cites] N Engl J Med. 1999 Jan 14;340(2):101-7 [9887161.001]
  • [Cites] Int J Oncol. 1999 May;14(5):979-85 [10200351.001]
  • [Cites] Am J Clin Nutr. 1999 May;69(5):842-56 [10232622.001]
  • [Cites] Gut. 1999 Jul;45(1):45-50 [10369703.001]
  • [Cites] Calcif Tissue Int. 1999 Oct;65(4):295-306 [10485982.001]
  • [Cites] Am J Clin Nutr. 2004 Nov;80(5):1358-65 [15531687.001]
  • [Cites] J Nutr. 2004 Dec;134(12 Suppl):3463S-3471S [15570055.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):493-8 [15695391.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):525-8 [15734982.001]
  • [Cites] Am J Physiol Renal Physiol. 2005 Jul;289(1):F8-28 [15951480.001]
  • [Cites] Int J Cancer. 2005 Oct 20;117(1):137-44 [15880532.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):287-96 [16353199.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Feb;57(2):107-21 [16326109.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):684-96 [16481636.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1178-86 [17379616.001]
  • [Cites] Cochrane Database Syst Rev. 2008;(1):CD003548 [18254022.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2304-12 [10786699.001]
  • [CommentIn] Cancer Prev Res (Phila). 2009 Mar;2(3):197-9 [19258545.001]
  • (PMID = 19258546.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA104637-01; United States / NCI NIH HHS / CA / R01 CA104637; United States / NCI NIH HHS / CA / R01 CA104637-01
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Placebos; 1406-16-2 / Vitamin D; 1C6V77QF41 / Cholecalciferol; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ NIHMS120314; NLM/ PMC2712935
  •  go-up   go-down


Advertisement
4. Graefe T, Wollina U, Schulz H, Burgdorf W: Muir-Torre syndrome - treatment with isotretinoin and interferon alpha-2a can prevent tumour development. Dermatology; 2000;200(4):331-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Muir-Torre syndrome - treatment with isotretinoin and interferon alpha-2a can prevent tumour development.
  • A 57-year-old man presented with multiple sebaceous tumours, kerato-acanthomas, verrucous carcinoma of the nose, renal cell and transitional cell carcinomas of the left kidney, adenoma of the colon and a positive family history of colon carcinoma.
  • 3 x 10(6) U three times a week along with 50 mg isotretinoin daily as well as topical isotretinoin gel.
  • During a follow-up of 29 months, only 1 sebaceous skin tumour developed and was removed, whereas more than 30 such skin tumours had been surgically removed during the last 3 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Multiple Primary / drug therapy. Sebaceous Gland Neoplasms / drug therapy
  • [MeSH-minor] Humans. Interferon-alpha / administration & dosage. Isotretinoin / administration & dosage. Male. Middle Aged. Recombinant Proteins. Skin / drug effects. Skin / pathology. Syndrome

  • Genetic Alliance. consumer health - Keratoacanthoma.
  • Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 10894967.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 47RRR83SK7 / interferon alfa-2a; EH28UP18IF / Isotretinoin
  •  go-up   go-down


5. Fromont G, Barcat L, Gaudin J, Irani J: Revisiting the immunophenotype of nephrogenic adenoma. Am J Surg Pathol; 2009 Nov;33(11):1654-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Revisiting the immunophenotype of nephrogenic adenoma.
  • Nephrogenic adenoma (NA) is a rare benign lesion of the urinary tract.
  • Although its histogenesis is still debated, several reports suggest that the lesion has a renal tubular cell origin or differentiation.
  • Because all the previous studies have used an avidin-biotin (AB) detection procedure, and because cells with tubular renal differentiation are likely to contain a high level of endogenous biotin, we investigated in NA the expression of several markers including AMACR, using both AB and biotin-free detection systems.
  • We assessed the expression of p63, cytokeratins 7 and 20, CD10 (proximal tubule marker), MUC1 (distal tubule marker), PAX2, and AMACR on 14 NAs (from 6 patients) grouped on a tissue microarray.
  • The tissue microarray also included renal, urothelial, and prostate tissues.
  • Detection with the AB procedure leads to nonspecific staining in kidney samples and NA.
  • These findings provide supporting evidence that NA has the differentiation of distal renal tubules, and strongly suggest that AMACR, when detected with a biotin-free procedure, can be used as a reliable marker for distinguishing NA from prostate cancer.
  • [MeSH-major] Adenoma / immunology. Immunophenotyping / methods. Urologic Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Child. Diagnosis, Differential. Female. Fluorescent Antibody Technique, Indirect. Humans. Kidney Tubules / enzymology. Male. Middle Aged. Prostatic Neoplasms / diagnosis. Racemases and Epimerases / metabolism. Tissue Array Analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19730362.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


6. Gupta D, Bronstein IB, Holden JA: Expression of DNA topoisomerase I in neoplasms of the kidney: correlation with histological grade, proliferation, and patient survival. Hum Pathol; 2000 Feb;31(2):214-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of DNA topoisomerase I in neoplasms of the kidney: correlation with histological grade, proliferation, and patient survival.
  • Renal cell carcinoma is an inherently chemotherapeutically resistant neoplasm.
  • Because of this, new drugs targeting this tumor are needed.
  • One class of new anticancer drug targets the enzyme DNA topoisomerase I.
  • Laboratory data indicate that cells sensitive to topo I targeting drugs contain high topo I levels.
  • To determine whether some renal cell carcinomas contain elevated topo I and might therefore be targets of topo I active antitumor agents, we used a new immunohistochemical stain for topo I to determine the expression of the enzyme in 51 tumors of the kidney.
  • Increased topo I expression was found in 4 of 11 (36%) grade 3 renal cell carcinomas and in 8 of 8 (100%) grade 4 renal cell carcinomas.
  • Normal topo I expression was observed in all adenomas, oncocytomas, and grade 1 and grade 2 renal cell carcinomas.
  • Because topo I targeted anticancer drugs are S-phase specific, topo II-alpha and MIB-1 proliferation indices also were performed.
  • We hypothesize that these tumors might be susceptible to topo I anticancer drug therapy.
  • [MeSH-major] DNA Topoisomerases, Type I / analysis. Kidney Neoplasms / enzymology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adenoma / enzymology. Adenoma / mortality. Adenoma / pathology. Adenoma, Oxyphilic / enzymology. Adenoma, Oxyphilic / mortality. Adenoma, Oxyphilic / pathology. Adolescent. Adult. Aged. Carcinoma, Renal Cell / enzymology. Carcinoma, Renal Cell / mortality. Carcinoma, Renal Cell / pathology. Cell Division. Female. Humans. Immunohistochemistry. Male. Middle Aged. Sarcoma / enzymology. Sarcoma / mortality. Sarcoma / pathology. Survival Rate

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10685636.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] EC 5.99.1.2 / DNA Topoisomerases, Type I
  •  go-up   go-down


7. Zhang MZ, Xu J, Yao B, Yin H, Cai Q, Shrubsole MJ, Chen X, Kon V, Zheng W, Pozzi A, Harris RC: Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans. J Clin Invest; 2009 Apr;119(4):876-85
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans.
  • Studies have shown that COX-2-derived PGE2 promotes CRC progression, and both nonselective COX inhibitors (NSAIDs) and selective COX-2 inhibitors (such as glucocorticoids) reduce the number and size of colonic adenomas.
  • We found that expression of 11beta-hydroxysteroid dehydrogenase type II (11betaHSD2), which converts active glucocorticoids to inactive keto-forms, increased in human colonic and Apc+/min mouse intestinal adenomas and correlated with increased COX-2 expression and activity.
  • Furthermore, pharmacologic inhibition or gene silencing of 11betaHSD2 inhibited COX-2-mediated PGE2 production in tumors and prevented adenoma formation, tumor growth, and metastasis in mice.
  • Therefore, 11betaHSD2 inhibition represents what we believe to be a novel approach for CRC chemoprevention and therapy by increasing tumor glucocorticoid activity, which in turn selectively blocks local COX-2 activity.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLYCYRRHIZIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Food Chem Toxicol. 1993 Apr;31(4):303-12 [8386690.001]
  • [Cites] Steroids. 1993 Apr;58(4):153-6 [8493704.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1183-8 [7926468.001]
  • [Cites] N Engl J Med. 1995 Sep 7;333(10):609-14 [7637720.001]
  • [Cites] J Biol Chem. 1995 Sep 15;270(37):22044-9 [7665626.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):657-62 [9012840.001]
  • [Cites] J Clin Invest. 1997 May 1;99(9):2254-9 [9151799.001]
  • [Cites] Cell. 1998 May 29;93(5):705-16 [9630216.001]
  • [Cites] Cancer. 1998 Jun 15;82(12):2326-33 [9635524.001]
  • [Cites] Am J Health Syst Pharm. 1999 Jan 15;56(2):106-7 [10030522.001]
  • [Cites] Arch Biochem Biophys. 2005 Mar 1;435(1):50-5 [15680906.001]
  • [Cites] Am J Gastroenterol. 2002 Jan;97(1):13-21 [11808936.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):544-51 [11905709.001]
  • [Cites] Semin Oncol. 2002 Apr;29(2):126-35 [11951210.001]
  • [Cites] Science. 2002 Apr 19;296(5567):539-41 [11964481.001]
  • [Cites] Gut. 2002 Jun;50(6):857-60 [12010890.001]
  • [Cites] Am J Physiol Renal Physiol. 2002 Sep;283(3):F509-16 [12167602.001]
  • [Cites] FEBS Lett. 2002 Nov 6;531(2):278-84 [12417326.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] Oncogene. 2003 Mar 20;22(11):1663-7 [12642869.001]
  • [Cites] Curr Opin Pharmacol. 2003 Aug;3(4):404-11 [12901950.001]
  • [Cites] J Steroid Biochem Mol Biol. 2003 Jun;85(2-5):415-21 [12943730.001]
  • [Cites] Circulation. 2003 Dec 16;108(24):3017-23 [14638539.001]
  • [Cites] J Biol Chem. 2004 Jul 9;279(28):29797-804 [15123663.001]
  • [Cites] J Biol Chem. 2005 Feb 4;280(5):3217-23 [15542609.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5040-4 [11016626.001]
  • [Cites] Hum Exp Toxicol. 2000 Aug;19(8):434-9 [11125713.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3358-63 [11248083.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18075-81 [11278548.001]
  • [Cites] J Immunol. 2001 Jul 1;167(1):469-74 [11418684.001]
  • [Cites] J Clin Invest. 2005 Mar;115(3):642-52 [15765147.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1092-102 [15713943.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1071-80 [15713944.001]
  • [Cites] Neoplasia. 2005 Feb;7(2):118-27 [15802017.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2840-55 [15837998.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2005 Jun;288(6):R1767-73 [15718388.001]
  • [Cites] Int J Cancer. 2005 Aug 10;116(1):52-61 [15756690.001]
  • [Cites] Science. 2005 Dec 2;310(5753):1504-10 [16293724.001]
  • [Cites] J Clin Invest. 2006 Jan;116(1):4-15 [16395396.001]
  • [Cites] Dig Dis Sci. 2006 Mar;51(3):603-9 [16614974.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):873-84 [16943400.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 24;103(43):16045-50 [17043228.001]
  • [Cites] J Pharmacol Exp Ther. 2008 Dec;327(3):941-53 [18772318.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15280-5 [10611376.001]
  • [Cites] Kidney Int. 2000 Apr;57(4):1307-12 [10760059.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] FASEB J. 2002 Jan;16(1):36-44 [11772934.001]
  • [Cites] Acta Physiol Scand. 2004 Aug;181(4):543-7 [15283769.001]
  • [Cites] Horm Metab Res. 2004 Jul;36(7):437-44 [15305225.001]
  • [Cites] Science. 1988 Oct 28;242(4878):583-5 [2845584.001]
  • [Cites] N Engl J Med. 1991 Dec 5;325(23):1593-6 [1669840.001]
  • [Cites] J Steroid Biochem Mol Biol. 1992 Mar;41(3-8):739-45 [1562548.001]
  • [Cites] Science. 1992 Oct 16;258(5081):468-71 [1411543.001]
  • [CommentIn] J Clin Invest. 2009 Apr;119(4):760-3 [19348044.001]
  • (PMID = 19307727.001).
  • [ISSN] 1558-8238
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA97386; United States / NIDDK NIH HHS / DK / DK48831; United States / NCI NIH HHS / CA / R01 CA094849; United States / NIDDK NIH HHS / DK / P50 DK039261; United States / NIDDK NIH HHS / DK / R01 DK048831; United States / NIDDK NIH HHS / DK / DK39261; United States / NIDDK NIH HHS / DK / R01 DK074359; United States / NCI NIH HHS / CA / R01 CA097386; United States / NIDDK NIH HHS / DK / DK74359; United States / NCI NIH HHS / CA / CA94849; United States / NIDDK NIH HHS / DK / DK62794; United States / NIDDK NIH HHS / DK / R01 DK062794
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Enzyme Inhibitors; 0 / RNA, Small Interfering; 0 / Receptors, Glucocorticoid; 6FO62043WK / Glycyrrhizic Acid; EC 1.1.1.146 / 11-beta-Hydroxysteroid Dehydrogenase Type 2; EC 1.14.99.- / Ptgs2 protein, mouse; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  • [Other-IDs] NLM/ PMC2662561
  •  go-up   go-down


8. Egea Camacho J, Fernández del Busto E, González de Zárate J, Trueba Arguiñarena FJ, Sanz Lucas FJ, Pascual Samaniego M: [Hypertension emergency during surgery of renal carcinoma associated with non-diagnosed pheochromocytoma]. Arch Esp Urol; 2001 Sep;54(7):707-11
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hypertension emergency during surgery of renal carcinoma associated with non-diagnosed pheochromocytoma].
  • [Transliterated title] Emergencia hipertensiva durante la cirugía de un carcinoma renal asociado a feocromocitoma no diagnosticado.
  • OBJECTIVE: To present an uncommon association of renal carcinoma with an undiagnosed ipsilateral pheochromocytoma that caused severe cardiovascular disorders during surgical treatment of the renal carcinoma, and emphasize the need for careful assessment of these adrenal nodules before resection although they may appear to be clinically irrelevant.
  • METHODS: A 61-year-old male with mild arterial hypertension controlled with drug therapy for 40 years was diagnosed as having a right renal hypernephroma and a probable adrenal adenoma by IVP, abdominal ultrasound, CT, bone scintiscan and renal arteriography.
  • The patient developed severe hypertension intraoperatively, which was controlled by administration of lidocaine, nitroglycerine, sodium nitroprusside and labetalol.
  • RESULTS: The pathological analysis showed clear cell renal adenocarcinoma and pheochromocytoma.
  • [MeSH-major] Adrenal Gland Neoplasms / complications. Carcinoma, Renal Cell / surgery. Hypertension / etiology. Intraoperative Complications / etiology. Kidney Neoplasms / surgery. Pheochromocytoma / complications


9. Pan CC, Chen PC, Ho DM: The diagnostic utility of MOC31, BerEP4, RCC marker and CD10 in the classification of renal cell carcinoma and renal oncocytoma: an immunohistochemical analysis of 328 cases. Histopathology; 2004 Nov;45(5):452-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic utility of MOC31, BerEP4, RCC marker and CD10 in the classification of renal cell carcinoma and renal oncocytoma: an immunohistochemical analysis of 328 cases.
  • AIMS: To demonstrate the diagnostic utility of MOC31, BerEP4, renal cell carcinoma marker (RCC Ma) and CD10 in the classification of RCC and renal oncocytoma, based upon a comprehensive immunohistochemical analysis.
  • METHODS AND RESULTS: Immunohistochemistry was performed on 328 samples consisting of 256 clear cell/conventional, 27 papillary, 28 chromophobe, five collecting duct, five unclassified RCCs and seven renal oncocytomas using antibodies MOC31, BerEP4 and antibodies against cytokeratins (KL-1, CAM5.2, 34betaE12, cytokeratin 7), RCC Ma, epithelial membrane antigen, E-cadherin, CD10, CD15 and vimentin.
  • MOC31 and BerEP4 chiefly labelled distal tubules of normal kidney while RCC Ma and CD10 labelled the proximal tubules.
  • Twenty-three chromophobe RCCs (82%) were reactive for MOC31, while only four clear cell RCCs and three papillary RCCs were positive for this marker.
  • Clear cell RCCs were characterized by a high positive rate for CD10 (82%) and a low positive rate for BerEP4 (27%).
  • All renal oncocytomas were negative for MOC31 and CD10.
  • The CD10+/BerEP4- profile and RCC Ma+/BerEP4+ profile achieve moderate sensitivity and good specificity for clear cell RCC and papillary RCC, respectively.
  • The non-reactivity for both MOC31 and CD10 is helpful in distinguishing renal oncocytoma from RCC.
  • When properly selected, antibodies have immunohistochemical diagnostic utility for the classification of renal cortical epithelial tumours.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Biomarkers, Tumor. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Mitogen-Activated Protein Kinases. Neprilysin

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15500648.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / human epithelial antigen-125; EC 2.7.11.22 / MOK protein, human; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


10. Dasanu CA, Alexandrescu DT: Bilateral perinephric diffuse large B-cell lymphoma and synchronous renal oncocytoma. South Med J; 2008 Feb;101(2):196-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral perinephric diffuse large B-cell lymphoma and synchronous renal oncocytoma.
  • An elderly patient who presented with bilateral perinephric diffuse large B-cell lymphoma and concomitant oncocytoma of the same location is reported.
  • Because of the patient's other medical conditions, systemic chemotherapy was not deemed feasible.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Kidney Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Aged, 80 and over. Humans. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - Oncocytoma renal.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18364624.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Kauffman EC, Barocas DA, Chen YT, Yang XJ, Scherr DS, Tu JJ: Differential expression of KAI1 metastasis suppressor protein in renal cell tumor histological subtypes. J Urol; 2009 May;181(5):2305-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of KAI1 metastasis suppressor protein in renal cell tumor histological subtypes.
  • PURPOSE: The similar appearance of renal tumor histological subtypes can complicate differential diagnoses.
  • This problem is most notable for the chromophobe subtype of renal cell carcinoma, which can be histologically indistinguishable from oncocytoma with investigational molecular markers failing to provide reliable differentiation.
  • KAI1 is a metastasis suppressor gene whose expression correlates inversely with the metastatic potential of most solid tumor cancer types.
  • We tested the hypothesis that KAI1 is differentially expressed among renal tumor histological subtypes.
  • MATERIALS AND METHODS: Immunohistochemical staining for KAI1 protein was performed in 152 nephrectomy specimens, including 48 clear cell, 35 papillary and 31 chromophobe renal cell carcinoma samples, 28 oncocytomas and 10 tumor-free kidneys.
  • KAI1 mRNA levels were compared by quantitative reverse transcriptase-polymerase chain reaction in an additional 22 chromophobe renal cell carcinoma and oncocytoma samples.
  • RESULTS: In all 10 tumor-free kidneys KAI1 protein was detected exclusively in distal tubule cell membranes.
  • Of the tumor specimens KAI1 protein was absent in all papillary renal cell carcinoma specimens.
  • It was present in only 1 of 48 clear cell renal cell carcinomas (2%) and 2 of 28 oncocytomas (7%) but only at low levels.
  • In contrast, 27 of 31 chromophobe renal cell carcinoma specimens (87%) expressed KAI1 protein, most at moderate or high levels.
  • The diagnostic accuracy of KAI1 immunostaining for discerning chromophobe renal cell carcinoma from oncocytoma was 90% with similar results observed at the RNA level.
  • CONCLUSIONS: KAI1 is an accurate biomarker for chromophobe renal cell carcinoma that may aid in the diagnostic differentiation of chromophobe renal cell carcinoma from oncocytoma.
  • It remains to be determined whether KAI1 expression contributes to the low metastatic potential of chromophobe renal cell carcinoma.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / pathology. Extracellular Matrix Proteins / metabolism. Kidney Neoplasms / genetics. Kidney Neoplasms / pathology. Nerve Tissue Proteins / metabolism
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biopsy, Needle. Case-Control Studies. Diagnosis, Differential. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Nephrectomy. Prognosis. Reference Values. Risk Assessment. Sampling Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19303095.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Extracellular Matrix Proteins; 0 / KAL1 protein, human; 0 / Nerve Tissue Proteins
  •  go-up   go-down


12. Cao Y, Karsten U, Zerban H, Bannasch P: Expression of MUC1, Thomsen-Friedenreich-related antigens, and cytokeratin 19 in human renal cell carcinomas and tubular clear cell lesions. Virchows Arch; 2000 Feb;436(2):119-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of MUC1, Thomsen-Friedenreich-related antigens, and cytokeratin 19 in human renal cell carcinomas and tubular clear cell lesions.
  • The expression of MUC1, MUC2, mucin-associated Thomsen-Friedenreich-related antigens (TF, sialosyl-TF, Tn, and sialosyl-Tn), and cytokeratin 19 (CK19) was systematically investigated in situ in 58 resected human kidney tumours, surrounding tissue of normal appearance, and two normal kidneys obtained at autopsy, using monoclonal antibodies.
  • In kidney tissues of normal appearance, TF, s-TF, MUC1 and CK19 were positive in distal tubules and collecting ducts but negative in proximal tubules.
  • In contrast, MUC2, Tn, and s-Tn were negative throughout the normal renal tubular system.
  • Almost all renal cell carcinomas (RCCs) showed strong immunoreactivity for MUC1, but all were negative for MUC2.
  • In addition, the immunomorphological characteristics of the majority of clear-cell RCCs and clear/granular RCCs with anti-MUC1 and anti-CK 19 closely resembled those of the collecting duct and the distal tubule rather than the proximal tubule.
  • In the renal tissue of otherwise normal appearance adjacent to clear-cell RCCs and clear/granular RCCs, clear cells with excessive storage of glycogen were often found in the collecting duct system, but only rarely in the proximal tubules.
  • These results suggest that the majority of clear-cell RCCs and clear/granular RCCs may originate from the collecting duct system.
  • [MeSH-major] Adenoma, Oxyphilic / metabolism. Antigens, Tumor-Associated, Carbohydrate / metabolism. Carcinoma, Renal Cell / metabolism. Keratins / metabolism. Kidney Neoplasms / metabolism. Kidney Tubules, Collecting / metabolism. Kidney Tubules, Distal / metabolism. Mucin-1 / metabolism. Peptide Fragments / metabolism

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10755601.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / MUC1 tandem repeat peptide; 0 / Mucin-1; 0 / Peptide Fragments; 3554-90-3 / Thomsen-Friedenreich antigen; 68238-35-7 / Keratins
  •  go-up   go-down


13. Kozakowski N, Soleiman A, Pammer J: BMI-1 expression is inversely correlated with the grading of renal clear cell carcinoma. Pathol Oncol Res; 2008 Mar;14(1):9-13
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BMI-1 expression is inversely correlated with the grading of renal clear cell carcinoma.
  • BMI-1 regulates cell proliferation and differentiation, is involved in stem cell maintenance and can act as an oncogene.
  • We investigated BMI-1 expression in healthy normal kidney and in 77 renal tumours by immunohistochemistry, and correlated it with tumour differentiation.
  • BMI-1 could regularly be demonstrated in distal tubules and in Bowman's capsule, whereas it was mostly lacking in proximal tubules, indicating that it may rather be a differentiation marker of different renal cell populations than a stem cell marker.
  • In contrast to previous studies demonstrating a correlation between BMI-1 expression and malignancy, we showed that its expression was inversely correlated with the differentiation grade of clear cell carcinoma.
  • Thus, in renal clear cell carcinomas BMI-1 is rather a differentiation marker lost in carcinomas with high malignancy than an oncogene involved in tumour progression.
  • [MeSH-major] Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / metabolism. Kidney Neoplasms / pathology. Nuclear Proteins / metabolism. Proto-Oncogene Proteins / metabolism. Repressor Proteins / metabolism
  • [MeSH-minor] Adenoma, Oxyphilic / metabolism. Adenoma, Oxyphilic / pathology. Blotting, Western. Cell Line, Tumor. Disease Progression. Humans. Immunohistochemistry. Kidney / metabolism. Kidney / pathology. Neoplastic Stem Cells / metabolism. Polycomb Repressive Complex 1. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Clear Cell Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2006 May;19(5):684-94 [16528373.001]
  • [Cites] J Clin Invest. 2004 Sep;114(6):795-804 [15372103.001]
  • [Cites] Lung Cancer. 2005 Jun;48(3):299-306 [15892997.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2477-90 [16339096.001]
  • [Cites] Kidney Int. 2002 Feb;61(2):387-95 [11849378.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12 ):6063-71 [16778178.001]
  • [Cites] J Cell Biol. 1998 Aug 24;142(4):887-98 [9722603.001]
  • [Cites] Curr Opin Genet Dev. 1997 Apr;7(2):249-58 [9115424.001]
  • [Cites] Nature. 2004 Mar 18;428(6980):337-41 [15029199.001]
  • [Cites] Development. 1995 Sep;121(9):2847-52 [7555711.001]
  • [Cites] Crit Rev Oncol Hematol. 2003 Feb;45(2):177-90 [12604128.001]
  • [Cites] Am J Surg Pathol. 1982 Oct;6(7):655-63 [7180965.001]
  • [Cites] Nature. 2003 May 15;423(6937):255-60 [12714970.001]
  • [Cites] Genes Dev. 1999 Oct 15;13(20):2678-90 [10541554.001]
  • [Cites] Am J Pathol. 2005 Feb;166(2):545-55 [15681837.001]
  • [Cites] Genes Dev. 1999 Oct 15;13(20):2691-703 [10541555.001]
  • [Cites] Cell. 2004 Aug 20;118(4):409-18 [15315754.001]
  • [Cites] Eur Urol. 2007 Aug;52(2):455-63 [17134822.001]
  • [Cites] J Clin Pathol. 2007 Feb;60(2):167-72 [16837630.001]
  • [Cites] Cancer Lett. 2004 Jan 20;203(2):217-24 [14732230.001]
  • [Cites] J Am Soc Nephrol. 2006 Sep;17 (9):2443-56 [16885410.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2409-12 [11289106.001]
  • [Cites] Blood. 2001 Jun 15;97(12 ):3896-901 [11389032.001]
  • [Cites] J Am Soc Nephrol. 2006 Nov;17(11):3028-40 [16988061.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1091-6 [16931953.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):957-60 [17527087.001]
  • [Cites] Trends Immunol. 2003 Oct;24(10 ):522-4 [14552834.001]
  • [Cites] Eur J Cancer. 2006 Jun;42(9):1213-8 [16632344.001]
  • [Cites] Breast. 2004 Oct;13(5):383-8 [15454193.001]
  • [Cites] Nature. 1999 Jan 14;397(6715):164-8 [9923679.001]
  • (PMID = 18347933.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / BMI1 protein, human; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / Repressor Proteins; EC 2.3.2.27 / Polycomb Repressive Complex 1
  •  go-up   go-down


14. Kuroda N, Guo L, Toi M, Naruse K, Miyazaki E, Hayashi Y, Yoshikawa C, Ashida S, Shuin T, Enzan H: Paxillin: application of immunohistochemistry to the diagnosis of chromophobe renal cell carcinoma and oncocytoma. Appl Immunohistochem Mol Morphol; 2001 Dec;9(4):315-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paxillin: application of immunohistochemistry to the diagnosis of chromophobe renal cell carcinoma and oncocytoma.
  • In this study, 91 renal tumors--65 conventional renal cell carcinomas (RCCs), 14 papillary RCCs, 6 chromophobe RCCs, 4 collecting duct carcinomas, 2 oncocytomas--were investigated for the immunohistochemical expression of paxillin.
  • In a normal kidney, paxillin was predominantly expressed in the cytoplasm of distal tubules, loops of Henle, collecting ducts, and vascular smooth muscle cells.
  • An immunoblot analysis confirmed the presence of paxillin in healthy kidney, chromophobe RCC, and oncocytoma.
  • These data suggest that paxillin possibly plays a role in signal transductions as a focal adhesion intervening between tumor cells and the extracellular matrix in renal tumors with collecting duct phenotypes such as chromophobe RCCs and oncocytomas, but not in conventional RCCs.

  • Genetic Alliance. consumer health - Chromophobe Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Oncocytoma renal.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11759057.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytoskeletal Proteins; 0 / Neoplasm Proteins; 0 / PXN protein, human; 0 / Paxillin; 0 / Phosphoproteins
  •  go-up   go-down


15. Zhang J, Kang SK, Wang L, Touijer A, Hricak H: Distribution of renal tumor growth rates determined by using serial volumetric CT measurements. Radiology; 2009 Jan;250(1):137-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of renal tumor growth rates determined by using serial volumetric CT measurements.
  • PURPOSE: To retrospectively determine the distribution of growth rates across different sizes and subtypes of renal cortical tumors by assessing tumor volume and maximum tumor diameter at serial volumetric computed tomographic (CT) examinations.
  • Fifty-three of 2304 patients (34 men, 19 women; mean age, 67 years +/- 10 [standard deviation; range, 39-88 years) who underwent nephrectomy from 1989 to 2006 did not receive preoperative chemotherapy or radiation therapy and underwent at least two preoperative contrast material-enhanced CT examinations (at least 3 months apart) with identical section thickness that was no more than one-fifth of longitudinal tumor diameter.
  • Reciprocal of doubling time (DT) (RDT) was calculated.
  • RESULTS: Thirty-two clear cell carcinomas, 10 papillary carcinomas, six chromophobe carcinomas, four oncocytomas, and one angiomyolipoma were analyzed.
  • DT ranged from -78476.54 to 18057.43 days (mean, -1230.73 days; median, 590.51 days).
  • Faster-growing tumors were more likely to be clear cell carcinomas, those of higher grade had higher growth rates.
  • Small renal tumors (<or=3.5 cm) were similar to larger tumors in subtype and growth rate.
  • Age at diagnosis correlated negatively with renal tumor growth rate (P = .03).
  • CONCLUSION: Growth rates in renal tumors of different sizes, subtypes, and grades represent a wide range and overlap substantially.
  • Small renal tumors appear to be similar to larger ones in nature.
  • [MeSH-major] Cone-Beam Computed Tomography / methods. Kidney Cortex / radiography. Kidney Neoplasms / radiography
  • [MeSH-minor] Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / radiography. Adenoma, Oxyphilic / surgery. Adult. Aged. Aged, 80 and over. Angiomyolipoma / pathology. Angiomyolipoma / radiography. Angiomyolipoma / surgery. Carcinoma, Papillary / pathology. Carcinoma, Papillary / radiography. Carcinoma, Papillary / surgery. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / radiography. Carcinoma, Renal Cell / surgery. Disease Progression. Female. Humans. Male. Mathematical Computing. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Tumor Burden

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2009.
  • [CommentIn] Radiology. 2013 Dec;269(3):949-50 [24261507.001]
  • [CommentIn] Radiology. 2009 Jul;252(1):314; author reply 314-5 [19561267.001]
  • [ErratumIn] Radiology. 2013 Dec;269(3):950
  • [ErratumIn] Radiology. 2009 Jul;252(1):318
  • (PMID = 19092093.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Hofer C, Kübler H, Hartung R, Breul J, Avril N: Diagnosis and monitoring of urological tumors using positron emission tomography. Eur Urol; 2001 Nov;40(5):481-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and monitoring of urological tumors using positron emission tomography.
  • The purpose of this article was to critically review the diagnostic value of positron emission tomography (PET) in urological oncology.
  • Urinary tract tumor assessment is hampered by the renal elimination of (18)F-fluorodeoxyglucose (FDG), the most commonly used PET radiopharmaceutical.
  • PET imaging offers no significant benefits over conventional imaging modalities for renal cell and bladder carcinomas.
  • As a result of the low metabolic activity of prostate cancer, PET does not differentiate adequately between adenoma and carcinoma, nor detect local recurrence after radical prostatectomy with sufficient sensitivity.
  • Further studies are required to determine the clinical value of retroperitoneal lymph node staging and recurrent disease detection in germ cell tumors.
  • Finally, encouraging early results exist for the use of serial PET measurements to predict and assess therapy response to chemotherapy which may also be valuable in urological oncology.
  • [MeSH-major] Tomography, Emission-Computed. Urogenital Neoplasms / radionuclide imaging
  • [MeSH-minor] Carcinoma, Renal Cell / radionuclide imaging. Fluorodeoxyglucose F18. Humans. Kidney Neoplasms / radionuclide imaging. Male. Prostatic Neoplasms / radionuclide imaging. Seminoma / radionuclide imaging. Sensitivity and Specificity. Testicular Neoplasms / radionuclide imaging. Urinary Bladder Neoplasms / radionuclide imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11752853.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 45
  •  go-up   go-down


17. Hunger-Battefeld W, Gajda M, Hansch A, Mandecka A, Müller UA, Wolf G: [Diagnostic pitfalls with Cushing's syndrome]. Internist (Berl); 2010 Mar;51 Suppl 1:293-302
Hazardous Substances Data Bank. HYDROCORTISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adrenal cortical carcinoma is a rare diagnosis and may present with hormone secretion.
  • A histological differentiation between an adrenal cortical adenoma and carcinoma can be very difficult.
  • However, a fast diagnosis including staging and complete surgical resection is pivotal for the prognosis of an adrenal cortical carcinoma.
  • Metastasing adrenal cortical carcinoma should be treated with a mitotane based chemotherapy, and inclusion in the "firm-act study" is highly recommended.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenocortical Adenoma / diagnosis. Carcinoma, Renal Cell / diagnosis. Cushing Syndrome / diagnosis. Kidney Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis
  • [MeSH-minor] Adrenal Cortex / pathology. Adrenalectomy. Circadian Rhythm / physiology. Diabetes Mellitus, Type 2 / etiology. Diagnosis, Differential. Disease Progression. Female. Follow-Up Studies. Humans. Hydrocortisone / blood. Hypertension / etiology. Kidney / pathology. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Obesity, Morbid / etiology. Weight Gain

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lab Invest. 1995 Apr;72(4):424-31 [7723281.001]
  • [Cites] World J Surg. 2008 Aug;32(8):1802-8 [18425548.001]
  • [Cites] J Endocrinol Invest. 2007 Sep;30(8):647-52 [17923795.001]
  • [Cites] Front Horm Res. 2004;32:110-26 [15281342.001]
  • [Cites] Surgery. 1992 Dec;112(6):963-70; discussion 970-1 [1455321.001]
  • [Cites] Cancer. 1995 Feb 1;75(3):860-4 [7828138.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1612-9 [12459628.001]
  • [Cites] World J Surg. 2001 Jul;25(7):891-7 [11572030.001]
  • [Cites] Presse Med. 1995 Nov 11;24(34):1605-7 [8545366.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):719-26 [10622498.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2027-37 [16551738.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2008 Apr;116(4):246-51 [18393131.001]
  • [Cites] Surgery. 2006 Dec;140(6):914-20; discussion 919-20 [17188138.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;420(1):65-70 [1539453.001]
  • [Cites] Endocr Pathol. 2005 Spring;16(1):13-22 [16000842.001]
  • [Cites] APMIS. 1998 Aug;106(8):807-17 [9744767.001]
  • [Cites] Rev Hosp Clin Fac Med Sao Paulo. 2002 Nov-Dec;57(6):251-6 [12612756.001]
  • [Cites] Horm Metab Res. 1998 Jun-Jul;30(6-7):436-9 [9694576.001]
  • [Cites] Endocr J. 2008 Mar;55(1):49-55 [18187873.001]
  • [Cites] Surgery. 1996 Feb;119(2):161-70 [8571201.001]
  • [Cites] Lab Invest. 1992 Feb;66(2):169-74 [1735954.001]
  • [Cites] Eur J Clin Invest. 2000 Dec;30 Suppl 3:58-62 [11281370.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jan;92(1):148-54 [17062775.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):941-50 [11844815.001]
  • [Cites] Cancer. 1985 Feb 15;55(4):766-73 [3967172.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • (PMID = 20012255.001).
  • [ISSN] 1432-1289
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


19. Kooyers TJ, Westerhof W: [Toxicological aspects and health risks associated with hydroquinone in skin bleaching formula]. Ned Tijdschr Geneeskd; 2004 Apr 17;148(16):768-71
Hazardous Substances Data Bank. HYDROQUINONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Renal adenomas and leukaemia occurred in animal experiments indicating the nephrotoxicity and carcinogenic properties of the substance.
  • [MeSH-major] Cosmetics / adverse effects. Hydroquinones / adverse effects. Hyperpigmentation / drug therapy. Skin / drug effects
  • [MeSH-minor] Administration, Topical. Dose-Response Relationship, Drug. Face. Humans. Ochronosis / chemically induced

  • MedlinePlus Health Information. consumer health - Cosmetics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15129564.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cosmetics; 0 / Hydroquinones; 123-31-9 / hydroquinone
  • [Number-of-references] 23
  •  go-up   go-down


20. Chang HJ, Oh SN, Park MY, Rha SE, Choi BG: Fraudulent retouching of digital radiographic images--a potential risk. Clin Radiol; 2010 Dec;65(12):967-73

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Ten representative key images were selected of aortic dissection, hepatocellular carcinoma, renal cell carcinoma, colon cancer, liver metastasis, hepatic cyst, gallbladder stones, splenic artery aneurysm, adrenal adenoma, and stomach cancer from abdominal computed tomography (CT) imaging performed in 2008.
  • The time to complete retouching was recorded for each image.
  • Radiologists were requested to make a diagnosis for the 10 images, and were then asked to identify possible retouched images.
  • The time taken to reach a decision in each case was recorded.
  • RESULTS: The time to complete retouching was 15.2±3.15 min.
  • None of the reviewers recognized that some images were retouched during diagnosis.
  • The rate of correct diagnosis was 90% (range 71.7-100%).
  • After reviewers were informed of possible image retouching, the detection rate of retouched images was 50% (40-58.3%).
  • There was no significant difference between residents and attending radiologists in the detection rate of retouched images (p=0.786).
  • The time to diagnosis and the time to detection of the retouched images were 15 (14-17) and 6 (5-7) min, respectively.
  • [MeSH-minor] Deception. Fraud. Humans. Insurance Claim Reporting / legislation & jurisprudence. Internship and Residency. Radiology. Republic of Korea. Software. Time Factors. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 21070899.001).
  • [ISSN] 1365-229X
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


21. Liu W, Tretiakova M, Kong J, Turkyilmaz M, Li YC, Krausz T: Expression of vitamin D3 receptor in kidney tumors. Hum Pathol; 2006 Oct;37(10):1268-78
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of vitamin D3 receptor in kidney tumors.
  • The kidney is not only a primary vitamin D target organ but also is a key site of vitamin D metabolism.
  • Recent studies have shown that vitamin D has important physiologic effects on proliferation and differentiation in a variety of benign and malignant cells.
  • Our preliminary immunohistochemical study showed that vitamin D receptor (VDR) was highly expressed in renal distal tubules and collecting ducts, whereas the renal proximal tubules and glomeruli did not express VDR.
  • These observations led us to study the expression of VDR in various kidney tumors to determine the possible diagnostic utility of VDR.
  • Paraffin tissue microarray (TMA) blocks were constructed containing core cylinders from clear cell (52), papillary (35), chromophobe (20), sarcomatoid (20), and metastatic (59) renal cell carcinomas (RCCs).
  • In addition, 30 clear cell RCCs and 3 collecting duct carcinomas were also studied using conventional sections.
  • Furthermore, VDR messenger RNA and protein expression was also quantified using real-time reverse transcriptase-polymerase chain reaction and Western blot analysis.
  • In contrast, VDR expression was focal/weak and present only in the peripheral regions of clear cell RCCs.
  • Vitamin D receptor was weakly positive in sarcomatoid variant RCCs (88% [14/16]) regardless of the type of associated original RCC.
  • Overall, VDR is a discriminative marker for renal cell tumors.
  • The preferential expression of VDR in chromophobe RCCs, oncocytomas, and collecting duct carcinomas is in agreement with the concept that these tumors differentiate toward epithelium lining the distal convoluted tubules and collecting ducts.
  • In addition, the focal and much weaker VDR expression in clear cell RCCs makes VDR valuable in distinguishing clear cell RCC from other types of RCCs.
  • [MeSH-major] Adenoma, Oxyphilic / metabolism. Carcinoma, Renal Cell / metabolism. Kidney Neoplasms / metabolism. Receptors, Calcitriol / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Gene Expression. Humans. Immunoenzyme Techniques. Male. Middle Aged. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16949927.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Calcitriol
  •  go-up   go-down


22. Díaz Guardiola P, Vega Piñero B, Alameda Hernando C, Pavón de Paz I, Iglesias Bolaños P, Guijarro de Armas G: [Primary hyperparathyroidism. An alternative to the surgery]. Endocrinol Nutr; 2009 Mar;56(3):132-5
Hazardous Substances Data Bank. FUROSEMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary hyperparathyroidism is caused by an adenoma/hyperplasia in the parathyroid glands in which hypercalcemia is mainly due to an increased secretion of parathormone (PTH).
  • The only definitive treatment is surgery.
  • There are some patients at high surgical risk or who refuse surgery, and whose hypercalcemia cannot be controlled with conventional medical therapy such as hydration, diuretics and/or oral biphosphonates.
  • We suggest the use of two drugs indicated for the treatment of hypercalcemia of other etiologies: zoledronic acid, a parenteral bisphosphonate, and cinacalcet, a calcimimetic agent that reduces PTH secretion.
  • We present the case of a woman with hypercalcemia due to primary hyperparathyroidism caused by an adenoma, who was treated with both drugs.
  • [MeSH-major] Adenoma / complications. Diphosphonates / therapeutic use. Hypercalcemia / drug therapy. Hyperparathyroidism, Primary / etiology. Imidazoles / therapeutic use. Naphthalenes / therapeutic use. Parathyroid Neoplasms / complications
  • [MeSH-minor] Aged, 80 and over. Breast Neoplasms / surgery. Carcinoma / surgery. Carcinoma, Renal Cell / physiopathology. Cinacalcet Hydrochloride. Comorbidity. Drug Therapy, Combination. Female. Fluid Therapy. Furosemide / therapeutic use. Humans. Kidney Function Tests. Kidney Neoplasms / physiopathology. Parathyroidectomy / contraindications. Treatment Refusal

  • Genetic Alliance. consumer health - Hyperparathyroidism, primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19627726.001).
  • [ISSN] 1575-0922
  • [Journal-full-title] Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición
  • [ISO-abbreviation] Endocrinol Nutr
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Imidazoles; 0 / Naphthalenes; 1K860WSG25 / Cinacalcet Hydrochloride; 6XC1PAD3KF / zoledronic acid; 7LXU5N7ZO5 / Furosemide
  •  go-up   go-down


23. Murphy JJ, Tawfeeq M, Chang B, Nadel H: Early experience with PET/CT scan in the evaluation of pediatric abdominal neoplasms. J Pediatr Surg; 2008 Dec;43(12):2186-92
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Positron emission tomography/computerized tomography (PET/CT) scan provides both functional and anatomical information in a single diagnostic test.
  • These included Burkitt's lymphoma (8), neuroblastoma (7), rhabdomyosarcoma (6), ovarian tumor (3), Wilms' tumor (2), hepatocellular carcinoma (2), paraganglioma (1), germ cell tumor (1), undifferentiated sarcoma (1), renal primitive neuroectodermal tumor (1), gastrointestinal stromal tumor (1), adrenocortical carcinoma (1), inflammatory pseudotumor (1), and adrenal adenoma (1).
  • These include (1) preoperative staging, (2) selection of appropriate site for biopsy, (3) identification of occult metastatic disease, (4) follow-up for residual or recurrent disease, and (5) assessment of response to chemotherapy.
  • [MeSH-major] Abdominal Neoplasms / radiography. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Drug Monitoring. Female. Fluorodeoxyglucose F18 / pharmacokinetics. Humans. Male. Neoplasm Staging / methods. Neoplasm, Residual. Postoperative Care / methods. Preoperative Care / methods. Radiopharmaceuticals / pharmacokinetics. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19040932.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


24. Misić M, Vidas Z, Skegro D, Kocman B, Jelić-Puskarić B, Kardum-Skelin I: Fine needle aspiration cytology of adrenocortical carcinoma--case report. Coll Antropol; 2010 Jun;34(2):665-9
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One year later on regular follow up, US revealed a suspicious growth measuring 65 x 43 mm in the projection of the lower pole of the right kidney.
  • The finding was verified by computerized tomography and the patient was reoperated on.
  • 8 months after the second operation and after 6 chemotherapy cycles according to EAP protocol, control CT showed enlarged para-aortic lymph nodes and a node along the upper pole of the right kidney.
  • Morphologically (histopathology and cytology), differential diagnosis includes adenoma on the one hand, and renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) on the other hand.
  • A combined evaluation of clinical features, size or weight, microscopic appearance, immunohistochemical and molecular genetic data is necessary to ensure a correct diagnosis.
  • [MeSH-minor] Biopsy, Fine-Needle / methods. Fatal Outcome. Female. Humans. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698150.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


25. Gola M, Doga M, Bonadonna S, Mazziotti G, Vescovi PP, Giustina A: Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects. Pituitary; 2006;9(3):221-9
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hypothalamic GHRH is secreted into the portal system, binds to specific surface receptors of the somatotroph cell and elicits intracellular signals that modulate pituitary GH synthesis and/or secretion.
  • Moreover, GHRH is synthesized and expressed in multiple extrapituitary tissues.
  • Excessive peripheral production of GHRH by a tumor source would therefore be expected to cause somatotroph cell hyperstimulation, increased GH secretion and eventually pituitary acromegaly.
  • Immunoreactive GHRH is present in several tumors, including carcinoid tumors, pancreatic cell tumors, small cell lung cancers, endometrial tumors, adrenal adenomas, and pheochromocytomas which have been reported to secrete GHRH.
  • Unique and unexpected clinical features in an acromegalic patient, including respiratory wheezing or dyspnea, facial flushing, peptic ulcers, or renal stones sometimes are helpful in alerting the physician to diagnosing non pituitary endocrine tumors.
  • If no facility to measure plasma GHRH is available, and in the absence of MRI evidence of pituitary adenoma, a CT scan of the thorax and abdominal ultrasound could be performed to exclude with good approximation the possibility of an ectopic GHRH syndrome.
  • Standard chemotherapy directed at GHRH-producing carcinoid tumors is generally unsuccessful in controlling the activated GH axis.
  • Therefore, although cytotoxic chemotherapy, pituitary surgery, or irradiation still remain available therapeutic options, long-acting somatostatin analogs are now preferred as a second-line therapy in patients with carcinoid tumors and ectopic GHRH-syndrome.
  • [MeSH-major] Acromegaly / etiology. Adenoma / secretion. Carcinoid Tumor / secretion. Growth Hormone-Releasing Hormone / secretion. Growth Hormone-Secreting Pituitary Adenoma / secretion. Neuroendocrine Tumors / secretion. Paraneoplastic Endocrine Syndromes / etiology
  • [MeSH-minor] Animals. Biomarkers, Tumor / blood. Diagnosis, Differential. Human Growth Hormone / blood. Humans. Insulin-Like Growth Factor I / metabolism. Treatment Outcome. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocrinol Metab Clin North Am. 1992 Sep;21(3):539-51 [1521511.001]
  • [Cites] Endocrinology. 1997 Nov;138(11):4543-51 [9348176.001]
  • [Cites] Eur J Endocrinol. 2005 Dec;153(6):737-40 [16322377.001]
  • [Cites] Semin Oncol. 1987 Sep;14(3):343-53 [2820064.001]
  • [Cites] Biochem Biophys Res Commun. 1982 Nov 16;109(1):152-8 [7159418.001]
  • [Cites] Endocrinology. 1985 Aug;117(2):457-67 [2862007.001]
  • [Cites] Endocr J. 1993 Feb;40(1):133-9 [7951487.001]
  • [Cites] J Endocrinol Invest. 1993 Sep;16(8):585-90 [8258646.001]
  • [Cites] Nature. 1983 Feb 17-23;301(5901):607-8 [6402707.001]
  • [Cites] Endocr Rev. 1998 Dec;19(6):717-97 [9861545.001]
  • [Cites] Endocr Rev. 1988 Aug;9(3):357-73 [3145190.001]
  • [Cites] Metabolism. 1991 May;40(5):519-23 [2023538.001]
  • [Cites] Domest Anim Endocrinol. 1997 Sep;14(5):358-66 [9347256.001]
  • [Cites] J Neurosci. 1996 Dec 15;16(24):8140-8 [8987839.001]
  • [Cites] J Endocrinol Invest. 2003 Feb;26(2):163-9 [12739745.001]
  • [Cites] Nature. 1983 Jun 9-15;303(5917):532-5 [6406907.001]
  • [Cites] J Clin Endocrinol Metab. 1984 May;58(5):796-803 [6423659.001]
  • [Cites] J Clin Endocrinol Metab. 1989 May;68(5):917-24 [2565913.001]
  • [Cites] Proc Soc Exp Biol Med. 1990 Mar;193(3):232-5 [2106141.001]
  • [Cites] Neurosurgery. 2002 Jun;50(6):1356-9; discussion 1360 [12015856.001]
  • [Cites] J Neuroendocrinol. 1989 Apr 1;1(2):109-15 [19210467.001]
  • [Cites] Endocrinology. 1976 Mar;98(3):580-9 [177264.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Mar;54(3):301-7 [11298081.001]
  • [Cites] Neuroendocrinology. 1990 May;51(5):572-5 [1693757.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Nov;80(11):3321-6 [7593445.001]
  • [Cites] Metabolism. 1990 Sep;39(9 Suppl 2):40-2 [1976218.001]
  • [Cites] N Engl J Med. 1990 Aug 2;323(5):322-7 [2164153.001]
  • [Cites] Endocrinology. 1984 Nov;115(5):2032-4 [6436012.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2797-802 [12788890.001]
  • [Cites] J Clin Endocrinol Metab. 1984 Aug;59(2):197-201 [6330151.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2104-9 [15671091.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Apr;82(4):1210-9 [9100598.001]
  • [Cites] Endocrinology. 1993 Sep;133(3):1029-34 [8103446.001]
  • [Cites] Pharmacol Res. 1996 Nov-Dec;34(5-6):247-68 [9076850.001]
  • [Cites] J Clin Endocrinol Metab. 1984 Nov;59(5):846-9 [6434585.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):221-6 [2891432.001]
  • [Cites] Metabolism. 1992 Dec;41(12):1291-4 [1281259.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S89-94 [11762359.001]
  • [Cites] Endocrinol Jpn. 1989 Apr;36(2):229-36 [2550207.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Jan;68(1):180-5 [2491860.001]
  • [Cites] J Clin Invest. 1980 Jan;65(1):43-54 [6243140.001]
  • [Cites] Physiol Rev. 1999 Apr;79(2):511-607 [10221989.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Jan;68(1):22-8 [2491864.001]
  • [Cites] Clin Endocrinol (Oxf). 1987 Sep;27(3):297-306 [2892599.001]
  • [Cites] FEBS Lett. 1996 Sep 23;394(1):1-4 [8925914.001]
  • [Cites] J Clin Endocrinol Metab. 1987 Mar;64(3):585-91 [3102543.001]
  • [Cites] Endocrinology. 1985 Jul;117(1):424-6 [2988927.001]
  • [Cites] J Endocrinol Invest. 2003;26(8 Suppl):4-7 [15233203.001]
  • [Cites] Nature. 1982 Nov 18;300(5889):276-8 [6292724.001]
  • [Cites] J Clin Invest. 1990 Jul;86(1):17-24 [1973173.001]
  • [Cites] Endocrinology. 1972 Oct;91(4):1071-8 [5051331.001]
  • [Cites] J Endocrinol Invest. 2003 Dec;26(12):1242-7 [15055479.001]
  • [Cites] J Endocrinol Invest. 2005;28(11 Suppl International):43-7 [16625844.001]
  • [Cites] J Clin Invest. 1982 Nov;70(5):965-77 [6290540.001]
  • [Cites] Endocr Rev. 1991 Nov;12(4):450-82 [1684746.001]
  • [Cites] Endocrinology. 1984 Apr;114(4):1082-5 [6423368.001]
  • [Cites] Endocrinology. 1992 Mar;130(3):1097-102 [1537276.001]
  • [Cites] Clin Endocrinol (Oxf). 1986 Feb;24(2):135-40 [2871948.001]
  • [Cites] Nature. 1983 Nov 3-9;306(5938):84-5 [6415487.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):526-9 [10690849.001]
  • [Cites] Nature. 1985 Mar 21-27;314(6008):279-81 [2858817.001]
  • [Cites] Endocrinology. 1985 Oct;117(4):1598-601 [3928335.001]
  • [Cites] Lancet. 1984 Aug 18;2(8399):401-2 [6147476.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Sep;83(9):3104-9 [9745411.001]
  • [Cites] Endocrinology. 1983 Nov;113(5):1726-31 [6194979.001]
  • [Cites] Nature. 1993 Jul 15;364(6434):208-13 [8391647.001]
  • [Cites] Eur J Endocrinol. 1995 Jan;132(1):12-24 [7850005.001]
  • [Cites] Am J Clin Pathol. 1986 Jan;85(1):13-20 [3000164.001]
  • [Cites] Eur J Endocrinol. 1998 Jul;139(1):59-71 [9703380.001]
  • [Cites] Clin Endocrinol (Oxf). 1976 Sep;5(5):503-13 [991433.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Sep;87(9):4054-8 [12213843.001]
  • [Cites] Science. 1982 Nov 5;218(4572):585-7 [6812220.001]
  • [Cites] Clin Endocrinol (Oxf). 1989 Apr;30(4):367-77 [2574645.001]
  • [Cites] Endocrinology. 1996 Apr;137(4):1326-31 [8625907.001]
  • [Cites] Endocr Rev. 1986 Aug;7(3):223-53 [2874984.001]
  • [Cites] Am J Med. 1984 Apr;76(4):605-16 [6424465.001]
  • [Cites] Science. 1975 Feb 7;187(4175):447-9 [1111113.001]
  • [Cites] J Clin Endocrinol Metab. 1985 Feb;60(2):370-5 [3917460.001]
  • [Cites] Cancer. 1991 May 15;67(10):2538-42 [2015554.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Oct;128(4):631-2 [15457172.001]
  • [Cites] Endocrinol Metab Clin North Am. 1992 Sep;21(3):575-95 [1521513.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3989-95 [11502843.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Feb;68(2):499-504 [2493033.001]
  • [Cites] Adv Tech Stand Neurosurg. 1995;22:3-53 [7495421.001]
  • [Cites] J Clin Endocrinol Metab. 1984 Oct;59(4):747-51 [6434578.001]
  • [Cites] Annu Rev Med. 1990;41:447-55 [2184742.001]
  • [Cites] J Endocrinol Invest. 1993 Jan;16(1):69-81 [8445159.001]
  • [Cites] Br Med J (Clin Res Ed). 1986 Apr 12;292(6526):981-2 [2870758.001]
  • [Cites] J Clin Endocrinol Metab. 1984 Jan;58(1):212-4 [6417155.001]
  • [Cites] Science. 1985 Oct 25;230(4724):461-3 [2864742.001]
  • [Cites] Mol Endocrinol. 1992 Oct;6(10):1734-44 [1333056.001]
  • [Cites] Eur J Endocrinol. 1997 Jun;136(6):553-65 [9225715.001]
  • [Cites] Ir J Med Sci. 2004 Oct-Dec;173(4):215-6 [16323617.001]
  • [Cites] Acta Endocrinol (Copenh). 1985 May;109(1):13-8 [3923754.001]
  • [Cites] Endocrinology. 1991 Feb;128(2):1151-8 [1671214.001]
  • [Cites] J Endocrinol Invest. 1994 Oct;17(9):717-22 [7868816.001]
  • [Cites] Brain Res. 1989 Feb 27;481(1):8-15 [2565134.001]
  • [Cites] Eur J Endocrinol. 1995 Sep;133(3):320-4 [7581949.001]
  • [Cites] Endocrinology. 1985 Apr;116(4):1334-40 [3918850.001]
  • (PMID = 17036195.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I; 9034-39-3 / Growth Hormone-Releasing Hormone
  • [Number-of-references] 101
  •  go-up   go-down


26. Longoni E, Berti GL, Paccaduscio A, Raimoldi A, Giola V, Pozzoni F, Russo R, Confalonieri S, Bacchioni AM, Di Marco BM: Metanephric adenoma: case report and review of the literature. Arch Ital Urol Androl; 2004 Sep;76(3):121-3
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metanephric adenoma: case report and review of the literature.
  • Metanephric adenomas are benign tumors frequently found post-mortem (from 7% to 22% of autopsies) which originate from distal tubules; they are generally small in dimensions (smaller than 1 cm) and located in the renal cortex.
  • Metanephric adenoma is an uncommon kind of renal adenoma with no malignant potentiality: from the clinical and diagnostic viewpoint its own greater importance depends on the probability of diagnostic misunderstanding with Wilms' tumor; furthermore its echographic, tomographic and arteriographic characteristics are often similar to small renal adenocarcinoma ones (100).
  • Polycytemia is frequently associated to metanephric adenoma as paraneoplastic syndrome and, more rarely, abdominal mass, abdominal pain, hematuria and hypertension (140).
  • The most important study on metanephric adenoma is the one realized by E.K.
  • An important radiological characteristic is that metanephric adenomas are more frequent calcificated than other histotypes and, from the pathological viewpoint, the most important differential element seems to be the smaller dimensions of its cells with hyperchromatic nuclei in the absence or lack in mitotic activity and in the absence of chromosome aberrations.
  • In the case of difficult histological diagnosis, cytogenetic and immunohistochemical analysis can be useful.
  • In conclusion, because it is impossible to distinguish in the preoperatory between the metaneprhic adenomas and the other tumoral types on the bases of the symptoms, dimensions or radiographic appearance, it is mandatory to treat it as malignant eteroformations in a therapeutical strategy, when it is possible.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15568303.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 9
  •  go-up   go-down


27. Ozkan E, Arslan N, Arslanoglu A, Karacalioglu AO: Decreased Tc-99m sestamibi uptake in a sternal brown tumor indicating response to anti metabolic therapy for secondary hyperparathyroidism. Clin Nucl Med; 2007 Aug;32(8):661-2
MedlinePlus Health Information. consumer health - Vitamin D.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased Tc-99m sestamibi uptake in a sternal brown tumor indicating response to anti metabolic therapy for secondary hyperparathyroidism.
  • Brown tumors are rare but serious complications of renal osteodystrophy, and can be treated by parathyroidectomy or by pharmacological treatment of hyperparathyroidism.
  • In addition to parathyroid lesions such as adenoma, hyperplasia, and carcinoma, brown tumors have been detected effectively by using dual phase Tc-99m sestamibi and Tl-201 chloride.
  • We describe an unusual case of brown tumor at the manibrium sterni which shows marked increased Tc-99m sestamibi uptake on the initial scan, with decreasing tracer activity on follow-up scan indicating a response to antimetabolic therapy.
  • [MeSH-major] Carcinoma, Giant Cell / radionuclide imaging. Hyperparathyroidism, Secondary / drug therapy. Mediastinal Neoplasms / radionuclide imaging. Technetium Tc 99m Sestamibi. Vitamin D / administration & dosage
  • [MeSH-minor] Adult. Female. Humans. Metabolic Clearance Rate / drug effects. Radiopharmaceuticals / pharmacokinetics. Sternum / metabolism. Sternum / radionuclide imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667448.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 1406-16-2 / Vitamin D; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down






Advertisement